EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Pathogenesis and treatment of extramedullary disease in multiple myeloma: current status, challenges and opportunities

Ruijun Dong, Tianyu Huang, Wenxiang Zhang, HongXia Li, Aili He, Rui Liu

Journal of Cancer Research and Clinical Oncology · 20.08.2026 · 152 (11)

DOI: 10.1007/s00432-026-06589-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cancer Research and Clinical Oncology, online erschienen am 20.08.2026. Verfasst von Ruijun Dong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extramedullary disease (EMD) represents an aggressive manifestation of multiple myeloma (MM) in which malignant plasma cells acquire the ability to survive independently of the bone marrow microenvironment. Based on the site of involvement, EMD is classified into extramedullary bone related (EMB) that partially depends on the bone marrow, and extramedullary extraosseous (EME) that spreads through bloodstream. EMD can affect any tissue or organ and is associated with poor clinical outcomes in patients with MM. The underlying pathogenesis of EMD remains incompletely understood, and no standardized treatment approach has been established to date. This review integrates recent advances in the molecular pathogenesis of EMD with emerging immunotherapeutic strategies, particularly CAR-T cell-based therapies, and discusses the major translational challenges and future directions for improving the management of EMD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaHumansTumor MicroenvironmentImmunotherapy

Stichwörter der Autor:innen

CAR-T cell therapyExtramedullary diseaseImmunotherapyPathogenesisTumor microenvironment

Autor:innen und Institutionen

  • Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
  • Xi'an Key Laboratory of Hematological Diseases, Xi'an, Shaanxi, China.
  • Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China. heaili@xjtu.edu.cn.
  • Xi'an Key Laboratory of Hematological Diseases, Xi'an, Shaanxi, China. heaili@xjtu.edu.cn.
  • Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China. sszhu250@stu.xjtu.edu.cn.
  • Xi'an Key Laboratory of Hematological Diseases, Xi'an, Shaanxi, China. sszhu250@stu.xjtu.edu.cn.

Zitieren

APA

Dong, R., Huang, T., Zhang, W., Li, H., He, A., & Liu, R. (2026). Pathogenesis and treatment of extramedullary disease in multiple myeloma: current status, challenges and opportunities. Journal of Cancer Research and Clinical Oncology, 152(11). https://doi.org/10.1007/s00432-026-06589-4

Vancouver

Dong R, Huang T, Zhang W, Li H, He A, Liu R. Pathogenesis and treatment of extramedullary disease in multiple myeloma: current status, challenges and opportunities. Journal of Cancer Research and Clinical Oncology. 2026;152(11). doi:10.1007/s00432-026-06589-4

BibTeX
@article{Dong2026,
  author = {Dong, Ruijun and Huang, Tianyu and Zhang, Wenxiang and Li, HongXia and He, Aili and Liu, Rui},
  title = {Pathogenesis and treatment of extramedullary disease in multiple myeloma: current status, challenges and opportunities},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2026},
  volume = {152},
  number = {11},
  doi = {10.1007/s00432-026-06589-4}
}
Kostenlos starten →